

John W Davis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8852415/publications.pdf>

Version: 2024-02-01

94
papers

2,691
citations

218677

26
h-index

197818

49
g-index

98
all docs

98
docs citations

98
times ranked

4062
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of MRI/US fusion-guided prostate biopsy on biopsy-naïve patients: A single urologist's experience. BJUI Compass, 2022, 3, 19-25.	1.3	2
2	Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. BJU International, 2021, 127, 340-348.	2.5	12
3	Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. European Urology, 2021, 79, 298-306.	1.9	24
4	Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design. European Urology Focus, 2021, 7, 71-77.	3.1	3
5	Prospective trial of regional (hockey-stick) prostate cryoablation: oncologic and quality of life outcomes. World Journal of Urology, 2021, 39, 3259-3264.	2.2	5
6	Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy. Cancer, 2021, 127, 1425-1431.	4.1	10
7	Editorial Comment. Journal of Urology, 2021, 205, 1088-1088.	0.4	0
8	Optimizing the diagnosis and management of ductal prostate cancer. Nature Reviews Urology, 2021, 18, 337-358.	3.8	21
9	Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 296.e21-296.e29.	1.6	24
10	Re: Randomized Comparison of Techniques for Control of the Dorsal Venous Complex During Robot-assisted Laparoscopic Radical Prostatectomy. European Urology, 2021, 79, 702-703.	1.9	1
11	Development and Validation of an Objective Scoring Tool to Evaluate Surgical Dissection: Dissection Assessment for Robotic Technique (DART). Urology Practice, 2021, 8, 596-604.	0.5	6
12	Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase. Urology, 2021, 155, 144-151.	1.0	2
13	Freehand versus Grid-Based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications. Journal of Urology, 2021, 206, 894-902.	0.4	12
14	Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. European Journal of Cancer, 2021, 157, 259-267.	2.8	4
15	Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort. Cancer, 2021, 127, 720-728.	4.1	7
16	Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer and Prostatic Diseases, 2020, 23, 136-143.	3.9	36
17	Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology, 2020, 138, 91-97.	1.0	6
18	Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer, 2020, 126, 506-514.	4.1	21

#	ARTICLE	IF	CITATIONS
19	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. JCO Precision Oncology, 2020, 4, 1228-1238.	3.0	2
20	Cancer Surgery Scheduling During and After the COVID-19 First Wave. Annals of Surgery, 2020, 272, e106-e111.	4.2	26
21	Adoption of Single-Port Robotic Prostatectomy: Two Alternative Strategies. Journal of Endourology, 2020, 34, 1230-1234.	2.1	8
22	Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. Nature Communications, 2020, 11, 4279.	12.8	52
23	Patterns of metastases of prostatic ductal adenocarcinoma. Cancer, 2020, 126, 3667-3673.	4.1	14
24	Re: Medium-term Oncologic Outcomes in a Large Cohort of Men Treated with Focal or Hemi-ablation Using High-intensity Focused Ultrasonography for Primary Localized Prostate Cancer. European Urology, 2020, 77, 558.	1.9	0
25	Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients. EBioMedicine, 2020, 52, 102616.	6.1	14
26	Surgical techniques to improve continence recovery after robot-assisted radical prostatectomy. Translational Andrology and Urology, 2020, 9, 3036-3048.	1.4	13
27	Retziusâ€sparing robotâ€sisted radical prostatectomy (RSâ€sRARP) vs standard RARP: it's time for critical appraisal. BJU International, 2019, 123, 5-7.	2.5	30
28	Diet quality and Gleason grade progression among localised prostate cancer patients on active surveillance. British Journal of Cancer, 2019, 120, 466-471.	6.4	8
29	Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. European Urology, 2019, 76, 418-424.	1.9	43
30	Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging. European Urology Oncology, 2019, 2, 257-264.	5.4	5
31	Outcomes of very highâ€srisk prostate cancer after radical prostatectomy: Validation study from 3 centers. Cancer, 2019, 125, 391-397.	4.1	37
32	Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort. OncoImmunology, 2019, 8, e1483303.	4.6	7
33	Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches. Journal of Urology, 2019, 202, 725-731.	0.4	62
34	Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of â€œregression to the meanâ€œ using routine clinical features with correlating biochemical relapse rates. Asian Journal of Andrology, 2019, 21, 598.	1.6	11
35	Focal therapy for localized prostate cancer: is there a â€œmiddle groundâ€œ between active surveillance and definitive treatment?. Asian Journal of Andrology, 2019, 21, 37.	1.6	8
36	Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies. Indian Journal of Urology, 2019, 35, 6.	0.6	23

#	ARTICLE	IF	CITATIONS
37	Surgeonâ€led prostate cancer lymph node staging: pathological outcomes stratified by robotâ€assisted dissection templates and patient selection. BJU International, 2018, 122, 66-75.	2.5	10
38	Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. European Urology, 2018, 74, 140-143.	1.9	16
39	Baseline and longitudinal plasma caveolinâ€1 level as a biomarker in active surveillance for earlyâ€stage prostate cancer. BJU International, 2018, 121, 69-76.	2.5	10
40	Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. International Journal of Radiation Oncology Biology Physics, 2018, 100, 374-382.	0.8	42
41	A decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 13.e19-13.e25.	1.6	6
42	Quality of life after brachytherapy or bilateral nerveâ€sparing robotâ€assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU International, 2018, 121, 540-548.	2.5	22
43	Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. European Urology, 2018, 74, 107-114.	1.9	54
44	The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2018, 70, 462-478.	3.9	65
45	Extended Pelvic Lymph Node Dissection in Bladder Cancer. Journal of Endourology, 2018, 32, S-49-S-54.	2.1	3
46	Salvage topical therapy for upper tract urothelial carcinoma. World Journal of Urology, 2018, 36, 2027-2034.	2.2	11
47	Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer and Prostatic Diseases, 2018, 21, 524-532.	3.9	37
48	Biomarker classification, validation, and what to look for in 2017 and beyond. BJU International, 2017, 119, 812-814.	2.5	7
49	Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncology Letters, 2017, 13, 1949-1957.	1.8	22
50	Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. European Urology, 2017, 72, 845-852.	1.9	79
51	Urinary continence recovery after radical prostatectomy â€ anatomical/reconstructive and nerveâ€sparing techniques to improve outcomes. BJU International, 2017, 120, 185-196.	2.5	22
52	Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. Journal of Endourology, 2017, 31, 946-953.	2.1	33
53	Risk of hospitalisation after primary treatment for prostate cancer. BJU International, 2017, 120, 48-55.	2.5	3
54	Robotic or Open Radical Prostatectomy in Men with Previous Transurethral Resection of Prostate. Urology Journal, 2017, 14, 2955-2960.	0.4	6

#	ARTICLE	IF	CITATIONS
55	Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy. Investigative and Clinical Urology, 2016, 57, S155.	2.0	4
56	NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 509-519.	4.9	268
57	Sequencing robot-assisted extended pelvic lymph node dissection prior to radical prostatectomy: a step-by-step guide to exposure and efficiency. BJU International, 2016, 117, 192-198.	2.5	7
58	CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nature Communications, 2016, 7, 11674.	12.8	118
59	Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU International, 2016, 118, 68-76.	2.5	27
60	Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine, 2016, 7, 85-93.	6.1	6
61	The implications of ageing and life expectancy in prostate cancer treatment. Nature Reviews Urology, 2016, 13, 289-295.	3.8	7
62	Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System. Clinical Genitourinary Cancer, 2016, 14, 130-138.	1.9	14
63	Minimally Invasive Access to the Prostate: The Concept of Surgical Space Creation. , 2016, , 3-15.		0
64	Pelvic Lymph Node Dissection: Robotic Surgery Efficiency and Space-Creation Techniques to Achieve an Extended Template. , 2016, , 143-150.		0
65	Editorial Comment for Xu et al.. Journal of Endourology, 2015, 29, 208-209.	2.1	0
66	Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells. Oncotarget, 2015, 6, 10175-10194.	1.8	14
67	Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget, 2015, 6, 41988-41996.	1.8	26
68	The International Prostate Forum introduction and history. Asian Journal of Andrology, 2015, 17, 863.	1.6	1
69	Impact of a Clinical Trial Initiative on Clinical Trial Enrollment in a Multidisciplinary Prostate Cancer Clinic. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 993-998.	4.9	4
70	Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact. BJU International, 2014, 114, 320-322.	2.5	25
71	Physician Variation in Management of Low-Risk Prostate Cancer. JAMA Internal Medicine, 2014, 174, 1450.	5.1	104
72	Learning Curve Assessment of Robot-Assisted Radical Prostatectomy Compared with Open-Surgery Controls from the Premier Perspective Database. Journal of Endourology, 2014, 28, 560-566.	2.1	44

#	ARTICLE	IF	CITATIONS
73	Robot-Assisted Pelvic Lymphadenectomy. , 2014, , 93-101.		0
74	Lymphadenectomy with Robotic Cystectomy. Current Urology Reports, 2013, 14, 59-63.	2.2	4
75	Correlation of histomorphologic findings and partial neurovascular bundle preservation during laparoscopic and robotic radical prostatectomy. Journal of Robotic Surgery, 2013, 7, 1-8.	1.8	2
76	A caseâ€“mixâ€“adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons. BJU International, 2013, 111, 184-185.	2.5	4
77	What have we learned from the <sc>P</sc>artin table update?. BJU International, 2013, 111, 5-5.	2.5	3
78	Salvaging failed radiation therapy: does the tumour location permit a less toxic approach?. BJU International, 2013, 112, 279-280.	2.5	0
79	Effectiveness of Postgraduate Training for Learning Extraperitoneal Access for Robot-Assisted Radical Prostatectomy. Journal of Endourology, 2011, 25, 1363-1369.	2.1	18
80	Robot Assisted Extended Pelvic Lymphadenectomy at Radical Cystectomy: Lymph Node Yield Compared With Second Look Open Dissection. Journal of Urology, 2011, 185, 79-84.	0.4	55
81	Robotâ€“assisted extended pelvic lymph node dissection (PLND) at the time of radical prostatectomy (RP): a videoâ€“based illustration of technique, results, and unmet patient selection needs. BJU International, 2011, 108, 993-998.	2.5	43
82	Self-rated health as a tool for estimating health-adjusted life expectancy among patients newly diagnosed with localized prostate cancer: a preliminary study. Quality of Life Research, 2011, 20, 713-721.	3.1	18
83	Radical prostatectomy findings in patients predicted to have lowâ€“volume/lowâ€“grade prostate cancer diagnosed by extendedâ€“core biopsies: an analysis of volume and zonal distribution of tumour foci. BJU International, 2010, 105, 1386-1391.	2.5	25
84	Initial experience of teaching robotâ€“assisted radical prostatectomy to surgeonsâ€“inâ€“training: can training be evaluated and standardized?. BJU International, 2010, 105, 1148-1154.	2.5	37
85	Quality of Life After Open or Robotic Prostatectomy, Cryoablation or Brachytherapy for Localized Prostate Cancer. Journal of Urology, 2010, 183, 1822-1829.	0.4	99
86	Robot-assisted radical cystectomy: An expert panel review of the current status and future direction. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 480-486.	1.6	28
87	Patients' Survival Expectations before Localized Prostate Cancer Treatment by Treatment Status. Journal of the American Board of Family Medicine, 2009, 22, 247-256.	1.5	28
88	Circulating tumor cell assays for the prognosis of prostate and colon cancers. Expert Opinion on Medical Diagnostics, 2009, 3, 293-301.	1.6	6
89	Randomized Phase II Trial Evaluation of Erectile Function after Attempted Unilateral Cavernous Nerve-Sparing Retropubic Radical Prostatectomy With Versus Without Unilateral Sural Nerve Grafting for Clinically Localized Prostate Cancer. European Urology, 2009, 55, 1135-1144.	1.9	62
90	PCA3 Molecular Urine Assay Correlates With Prostate Cancer Tumor Volume: Implication in Selecting Candidates for Active Surveillance. Journal of Urology, 2008, 179, 1804-1810.	0.4	255

#	ARTICLE	IF	CITATIONS
91	Circulating Tumor Cells in Peripheral Blood Samples From Patients With Increased Serum Prostate Specific Antigen: Initial Results in Early Prostate Cancer. Journal of Urology, 2008, 179, 2187-2191.	0.4	127
92	An Assessment of Quality of Life Following Radical Prostatectomy, High Dose External Beam Radiation Therapy and Brachytherapy Iodine Implantation as Monotherapies for Localized Prostate Cancer. Journal of Urology, 2007, 177, 2151-2156.	0.4	129
93	A nomogram for predicting low-volume/low-grade prostate cancer. Cancer, 2007, 110, 2441-2447.	4.1	64
94	Early nasogastric tube removal combined with metoclopramide after postchemotherapy retroperitoneal lymph node dissection for metastatic testicular nonseminomatous germ cell tumor. Urology, 2002, 59, 579-583.	1.0	8